Feb. 16. 2026
Osaka, Japan – February 16, 2026 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Motohiko Kimura) received approvals by the Ministry of Health, Labour and Welfare for Six generic drugs with Nine strengths. The five compounds marked with an asterisk below are approved for the first time as generics.
The list of approved products
1. BILASTINE Tablets, OD Tablets
| Generic name | Bilastine* |
|---|---|
| Strengths | Tablets: 20mg OD Tablets: 20mg |
| Brand products | Bilanoa® Tablets 20mg Bilanoa® OD Tablets 20mg |
2. DESLORATADINE Tablets
| Generic name | Desloratadine* |
|---|---|
| Strengths | Tablets: 5mg |
| Brand products | DESALEX® Tablets 5mg |
3. ELTROMBOPAG Tablets
| Generic name | Eltrombopag Olamine* |
|---|---|
| Strengths | Tablets: 12.5mg, 25mg |
| Brand products | REVOLADE® Tablets 12.5mg, 25mg |
4. ANAGRELIDE Capsules
| Generic name | Anagrelide Hydrochloride Hydrate* |
|---|---|
| Strengths | Capsules: 0.5mg |
| Brand products | AGRYLIN® Capsules 0.5mg |
5. FESOTERODINE FUMARATE Sustained-release Tablets
| Generic name | Fesoterodine Fumarate* |
|---|---|
| Strengths | Sustained-release Tablets: 4mg, 8mg |
| Brand products | Toviaz® Tablets 4mg, 8mg |
6. LUBIPROSTONE Capsules
| Generic name | Lubiprostone |
|---|---|
| Strengths | Capsules: 24μg |
| Brand products | Amitiza® Capsules 24μg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.